DeNovaMed
DeNovaMed is a pioneering pharmaceutical company dedicated to developing innovative antibiotics to combat bacterial infections and drug resistance. Their focus includes addressing serious health issues such as diabetic foot ulcers, bacterial infections, and antibiotic-resistant strains. The company leverages advanced drug design, computer-aided drug discovery, and a strong team of experts to create novel therapies with broad therapeutic potential. DeNovaMed aims to provide effective solutions to global health challenges posed by resistant bacteria and to lead in antibiotic innovation.
Industries
biotechnology
health-care
medical
pharmaceutical
Nr. of Employees
small (1-50)
DeNovaMed
Expertise Areas
- Antibacterial drug discovery
- Computer-aided drug design (computational medicinal chemistry)
- Novel mechanism-of-action development (lipid metabolism / ACP synthase targeting)
- Preclinical development and lead optimization
Key Technologies
- Computer-aided drug design (de novo molecular modeling)
- ACP synthase (AcpS) inhibition
- De novo small-molecule library synthesis
- Minimum inhibitory concentration (MIC) assays